Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
High-resolution image-based computational inner ear modelling for surgical planning of cochlear implantation (HEAR-EU)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Switzerland,Denmark,Austria
Call:  (FP7-HEALTH-2012-INNOVATION-2, 2012)
Start date: 2012-09-01
End date: 2015-08-31
Duration (months): 36.0
Total project cost (EUR): 4737501.0
EU funding (EUR): 3551284.75
Participants: 6
Project status: CLOSED

Cochlear implantation is a surgical procedure that aims to overcome hearing loss by direct electrical stimulation of the spiral ganglion cells in the cochlea of the inner ear. The surgical scenario of implantation surgery is very complex. It requires high clinical expertise in order to 1) efficiently access the surgical site, the cochlea, localize nearby critical structures (e.g. facial nerve) and 2) optimize the position of the implantable device (electrode array) inside the cochlea. Furthermore, there is a vast anatomical variability amongst patients. This makes individual optimal fitting an extremely difficult task and strongly influences the success of the surgery and subsequently hearing restoration. We hypothesize that a comprehensive understanding of the shape variability of the middle and inner ear among patients will enable the design improvement of hearing implants, and will be of assistance during surgical planning. Consequently, the aim of this project is: 1) to develop a novel high-resolution high-energy microCT device to obtain detailed images of the middle and inner ear, even in the presence of metallic implants, 2) to build a model of the shape variability of the middle and inner ear from high-resolution images, also incorporating functional information, 3) to build a computer-assisted patient-specific preoperative planning system, and 4) to improve the design of cochlear implant (CI) electrode arrays and associated insertion tools using a population-based optimization framework. All objectives revolve around the criteria of minimizing invasiveness, insertion-induced trauma and enhanced functional outcome through patient-specific frequency mapping. The consortium is composed of two research-intensive SMEs, one university hospital, two universities, and a large European enterprise. This project will lead to important strategic benefits for all partners, and very especially for the SMEs.

Keywords: sensory impairments,hearing loss,implantable devices,cochlear implantation surgery,high-resolution imaging,statistical shape models
Sharing Age A Sharing Approach to Promoting Science (ASAPS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Ireland,Belgium,United Kingdom,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2014-09-30
Duration (months): 24.0
Total project cost (EUR): 1194040.42
EU funding (EUR): 999001.0
Participants: 5
Project status: CLOSED

Although the EU has been funding superb health research, the general public who stand to benefit most, are frequently unaware of the research that is conducted on their behalf. Communications are becoming more social, digital and interactive. We propose a Sharing Approach to Promoting Science (ASAPS) that sets us apart from others because we aim to engage our audience from the outset and embed them in the creation of idea and content. We will use digital technologies, social media, user-experience design, and multiplatform story telling to increase the visibility of collaborative Europe wide aging research and technology development, that has real relevance for the general public. One of the primary ways in which older adults use the internet is to educate themselves regarding their health. We will deliver a sustainable digital platform, an interactive website, a multi-lingual package of films (3 viral films, 3 shorts, a 60 minute documentary), mobile apps, events and to address the digital divide more traditional media. Our approach is innovative and our consortium comprising, aging experts, world class scientists, a European network representing 160 ageing organizations with access to 28 million people over 50, award winning media professionals including a creative communications agency, a digital design company (specialists in interaction design for social web) and an award-winning factual film production are perfectly qualified to deliver our innovative Sharing Age campaign.

Keywords: communication,health,research,sharing,ageing,film,multi-platform,community,age,cognitive ageing,digital,social media,multiplatform,interactive,dissemination
Development of a bioartificial liver therapy in acute liver failure (BALANCE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,France,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-2, 2012)
Start date: 2012-06-01
End date: 2015-05-31
Duration (months): 36.0
Total project cost (EUR): 7743215.4
EU funding (EUR): 5996180.0
Participants: 5
Project status: CLOSED

In BALANCE, the companies Hep-Art, Pharmacell and BioPredic join forces with academic partners Amsterdam Medical Centre and University of Edinburgh to offer Acute Liver Failure (ALF) patients a bioartificial liver-support system for bridging the waiting period for liver transplantation or recovery of the diseased liver. ALF is a highly lethal disorder and liver transplantation is the only life-saving therapy. However, limited availability of donor livers severely reduces its impact. A bioartificial liver (BAL) may support ALF patients by temporary and extracorporeal treatment of their plasma through a bioreactor with functional human liver cells. The central objective of BALANCE is to develop a HepaRG-BAL that executes the three key liver functions for a clinically relevant period in ALF and to reach proof of safety and feasibility. What makes the HepaRG-BAL extremely potent is the unique combination of an ideal liver cell ecosystem and the introduction of the HepaRG cell line which is the only human cell line in the world that approaches human liver in its functionality. A two-staged approach will be adopted. Stage I is designed for in-vitro optimisation of the BAL and the human cell line and stage II comprises of the ex-vivo activities in which the optimized and upscaled BAL is tested and validated in pigs (controlled study). In addition approvement of a Phase I/IIa in humans will be prepared. . BALANCE will give birth to four main results: an optimised and validated BAL, a large scale manufacturing process, proof of concept in a large animal model of ALF and basic information for regulatory approval for future clinical application. Hep-Art will further pursue clinical development of the BAL towards EMA registration and marketing together with a large industrial partner. BioPredic will further exploit the HepaRG cells. Last but not least, BALANCE will strengthen the European competitive advantage in the field of bioartificial organs.

Keywords: bioartificial liver,liver failure,hepatocyte,clinical trial
Ambulatory Bio-Artificial Lung (AMBULUNG)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Sweden,United Kingdom,Italy,Germany,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-2, 2012)
Start date: 2012-07-01
End date: 2015-06-30
Duration (months): 36.0
Total project cost (EUR): 7416968.34
EU funding (EUR): 5650000.0
Participants: 5
Project status: CLOSED

Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death worldwide. Long-term respiratory support increases the life expectancy and the quality of life of COPD patients and decreases the cost of care. Currently available artificial lungs, such as Novalung’s iLA system, fail after ~ one month, mainly due to thrombus formation at the blood/machine interface. The size of current systems restrict patient mobility. We aim to create a wearable bioartificial lung (AmbuLung) for long-term application in an outpatient setting. The goals are to (1) miniaturise the existing iLA system, including the supporting technology and patient monitoring system; (2) cellularise the diffusion membrane with endothelial cells to decrease thrombogenicity and to increase the gas-exchange rate; and (3) evaluate the developed system in pre-clinical and clinical studies. The innovation includes (i) development of a novel alveolo-capillary gas-exchange membrane, functionalised with bioactive molecules and seeded with endothelial cells, ii) miniaturisation of mechanical and electronic device components, and (iii) novel vascular access system. For cellularisation, endothelial cells derived from FDA approved clinical grade human pluripotent stem cells will be used. Cell differentiation, scale-up, seeding, and maintenance will be performed using established automatable and scalable dynamic bioreactor technology. A mathematical model will be developed to predict and refine the function of this complex system in vitro and in vivo. AmbuLung will be evaluated in a pig model, assessing functionality, and non-thrombogenicity. The data will provide information required for potential clinical transfer. If successful, a clinical trial will be carried out on 5 COPD patients after acquisition of necessary regulatory approvals. Evaluation of efficacy of the intervention will be based on multidimensional health status grading.

Keywords: bioartificial organ,lung,artificial membrane,membrane oxygenator,alveolocapillary membrane,bioreactor,extracorporeal membrane oxygenator
ROutine diagnostic tool for Urinary Tract INfections caused by Esbl and carbapenamase producing bacteria (ROUTINE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,Belgium,Germany,Sweden,Finland
Call:  (FP7-HEALTH-2012-INNOVATION-2, 2012)
Start date: 2012-09-01
End date: 2016-02-29
Duration (months): 42.0
Total project cost (EUR): 3728649.6
EU funding (EUR): 2892869.0
Participants: 5
Project status: CLOSED

Treatment of Urinary Tract Infections (UTI) is currently initiated empirically because conventional diagnosis takes 2-3 days from sample to results. Moreover, the pharmaceutical pipeline is almost dry. Therefore, the last decade has globally witnessed a huge explosion of antibiotic (AB) resistance in Gram Negative Bacteria (GNB), which has drastically reduced the available AB therapy choices for UTI. The WHO considers this one of the major public health threats. Rapid detection of bacterial species and their AB susceptibility provides the main option to curb this development and prolong the lifetime of currently available antibiotics. In ROUTINE, 3 SMEs and 2 Universities will develop a prototype benchtop instrument that will rapidly (< 30 min) detect bacteria and characterize key antibiotics resistance profiles of ESBL (extended spectrum beta lactamase) and carbapenemase producing GNB directly from the patient urine at the point of care in outpatients and hospitals at a low cost (~20 €/test) and with near 100% sensitivity and specificity. Key factors to success are: 1. The consortium has an established collaboration through other projects 2. The starting point, builds on previous knowhow and the reader, cartridge and bioassay technologies developed within previous collaborations. 3. The “uncomplicated” raw urine sample material and the choice of technologies will ensure reaching the ground-breaking end goals in terms of assay time, cost, sensitivity, specificity and ease-of-use. 4. The designs, materials and processes used are familiar to regulatory authorities, which enable approval by e.g. FDA. 5. The 3 SMEs have experience in developing and bringing diagnostics products to the market. The project will lead to 1) a complete, tested, POC system, and 2) a tailor-made software algorithm for detection of AB resistant GNB, delivering a revolutionary tool in patient treatment, reducing morbidity and mortality, and curbing the spread of AB resistance.

Keywords: urinary tract infection uti,gram negative bacteria,antibiotics resistance,esbl,carbapenemase,detection,characterization,microfluidics,pcr,microarray,poct testing,rapid detection
Bottom-up reconstitution of a biomimetic bioartificial liver (RE-LIVER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,Germany,United Kingdom,Germany,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-2, 2012)
Start date: 2012-07-01
End date: 2015-06-30
Duration (months): 36.0
Total project cost (EUR): 5377150.8
EU funding (EUR): 4234877.0
Participants: 5
Project status: CLOSED

The liver, by way of its central role in both endogenous and exogenous metabolism, is one of the most well-studied organs in the human body. Hepatic tissue and its derivatives have a wide range of in-vivo and in-vitro applications from whole organ or partial lobe transplant, bioartificial ex-vivo devices, treatment of metabolic disorders to toxicology, drug metabolism and tissue regeneration. On the one hand, suitable donor livers for solid organ transplant are in short supply, while chronic liver diseases are on the increase both in Europe and world-wide. On the other hand, in-vitro and ex-vivo technologies for recapitulating liver function still fall short of reliability, consistency and predictivity, precluding many commercial applications. There is a dire need for innovative and reproducible methods for developing functional bioartificial livers or portions of liver which can be easily transplanted or reliably integrated into extracorporeal devices, essential for treating acute liver failure and other metabolic liver disorders. To avoid the risks and complications associated with animal/human matrices, yet furnish a reliable and reproducible 3D microarchitecture capable of maintaining the detoxification and metabolic functions of healthy human liver, our aim is to fabricate a novel hepatic lobuli ECM replica seeded with stable human hepatocytes and endothelial cells using the human liver as a design template through a bottom up approach. These cell-containing bioartificial constructs will be developed and characterized in vitro to assess metabolic function, protein production and angiogenic potential. They will then be implanted in animal models through minimally invasive techniques as a solid organ transplant alternative to recombinant Factor VIII-based therapy for patients with haemophilia A.

Keywords: bioartificial liver organoids,hepatocytes,hydrogels,bioreactor,transplantation,haemophilia a
Preclinical development of drugs and drug delivery technology for the treatment of inherited photoreceptor degeneration (DRUGSFORD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Italy,Sweden,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-2, 2012)
Start date: 2012-09-01
End date: 2016-08-31
Duration (months): 48.0
Total project cost (EUR): 6552814.21
EU funding (EUR): 4971428.0
Participants: 6
Project status: CLOSED

Dysregulation of cGMP is a pathological hallmark of inherited retinal degenerations (RD) affecting photoreceptors, the sensory cells of the retina. These RDs, including Retinitis Pigmentosa, Lebers Congenital Amaurosis, and Achromatopsia, are major causes of blindness, affecting approximately one in every 2000 individuals worldwide, and remain without effective treatment. In photoreceptors, cGMP is produced by retinal guanylyl cyclase (GC). The two main cGMP targets are cyclic nucleotide gated ion channels (CNGC) and cGMP-dependent protein kinase (PKG). Since attenuation of PKG and CNGC activity can reduce photoreceptor cell death, both proteins constitute potential targets to prevent RD. Recent data suggest that blocking retinal GC may also constitute a viable therapeutic approach. This consortium will study and develop targeted compounds and delivery systems aimed at preventing photoreceptor damage in preclinical disease models. Towards this goal, two SMEs have teamed up with three academic research groups focused on retinal degeneration: the German company BIOLOG specializes on development of cyclic nucleotide based drugs targeting PKG, CNGC, and GC; the Dutch company to-BBB develops systems to deliver drugs across the blood brain/retinal barrier (BBB, BRB, resp.); the groups of V. Marigo (Modena, Italy), P. Ekström (Lund, Sweden), and F. Paquet-Durand (Tübingen, Germany) have a strong and joint collaborative track record of studying photoreceptor degenerative mechanisms as well as on testing and evaluating drug treatment effects. Manufacturing of the most promising drugs fitted to a suitable delivery system will be scaled up towards clinical-size batches and studied towards efficacy, toxicology and off-target effects in model animals. The results of the project will allow the SMEs to further co-develop these drugs towards translation into clinical studies, addressing the high needs of RD patients and the high economic benefit of such therapies.

Keywords: drug development,drug delivery,liposome,nucleotide,photoreceptor,retinal degeneration
Innovative Midlife Intervention for Dementia deterrence (IN-MINDD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Ireland,Netherlands,France,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2015-10-31
Duration (months): 36.0
Total project cost (EUR): 3825936.0
EU funding (EUR): 2950530.0
Participants: 5
Project status: CLOSED

The European costs of dementia were estimated €177 billion and there is a growing gap between burden and budget. The debilitation associated with dementia makes it the most feared of conditions related to ageing . Modelling studies have estimated that if obesity rates dropped by 5%, dementia prevalence rates would be lower by 6% and a decline in physical inactivity rate by 5% would reduce dementia by 11%. For even a very small delay in disease onset of 1 year it is estimated that this would decrease dementia prevalence worldwide by 12 million fewer cases by 2050. The current European road map for the prevention of dementia indicated that prevention needs to start years before symptoms become apparent and needs to be multi-domain focussed. Dementia has complex and interacting aetiologies including, poor diet, cardiovascular problems, low exercise levels, low cognitive stimulation and mood problems. Clearly these risk factors are shared with many other diseases of ageing and interventions for them already exist around Europe in many cases. This project seeks to design and test a stare of the art electronic system for use in primary care to profile individual’s dementia risks and respond to those risks with a combination of the best available on-line strategies and locally sourced options. This will be achieved through advanced web search and aggregation technologies. This will enable comprehensive state of the art assessment, multi-use of programmes already designed for such risk modification, flexibility for the end user, and ease of use for primary care staff. The intervention is aimed at people in their sixth decade.

Keywords: dementia,risk modification,multi-domain,innovative
Development of a polymer strengthening coating system for glass containers (ONECOAT)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: Spain,Germany,France,Italy,Türkiye,Germany,Switzerland,United Kingdom
Call:  (FP7-SME-2012, 2012)
Start date: 2013-01-01
End date: 2014-12-31
Duration (months): 24.0
Total project cost (EUR): 1259286.67
EU funding (EUR): 943000.0
Participants: 8
Project status: CLOSED

Europe is the first producer of glass containers worlwide. However, various threats endanger the sustainability of this key industry: imports from low-cost labour countries outside Europe increased and more than 14,000 employments were lost in the European glass industry during the last 3 years. In addition, glass directly competes with other materials for packaging applications, especially plastics. It is cleaner, non-reactive, tasteless, chemically inert, fully recyclable and transparent but its surface is relatively brittle and prone to scratching which will result in premature breakage during the manipulation of the containers. Weight is also a drawback as an important percentage of the production costs from the food and beverage industries comes from transport of glass containers . Most of the glass containers produced nowadays are treated with an organic coating after formation to improve its resistance. There is a great demand from the glass containers industry itself for advanced coatings that allow improvement of mecahnical resistance and weight reduction. OneCoat will develop a coating material and application technology for glass containers based on polysiloxane (silicone) water emulsion with the following characteristics: - Competitive in price - Improved 30% overall resistance and 25% higher resistance to scratching allowing for a 10% reduction in weight of glass containers and increase of returns cycles (>40) - Highly versatile coating technology useful for different industry segments involved in the supply chain of glass containers (manufacturers, decorators and packaging companies). - Application by spraying from water emulsion and drying of the material with speeds of up to 800 bottles/min in modern production lines. - Compatible with the recycling process of glass. - Free of VOCs during the application process and safe for use in contact with foods and edible products

Keywords: glass containers,coating,polysiloxane,scratching resistance,packaging